ClinicalTrials.gg
CompletedNCT05680337Updated Jul 20, 2026

Auricular Vagus Stimulation and Heart Rate Variability

An interventional study of TENS in Vagus Nerve Stimulation and Heart Rate Variability, sponsored by Bakulev Scientific Center of Cardiovascular Surgery. Completed at 3 sites in Russia. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Bakulev Scientific Center of Cardiovascular Surgery · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Transcutaneous electrical stimulation of the auricular vagus nerve (TENS) is a promising method of neuromodulation of the autonomic nervous system in patients with various pathologies. The use of this method requires the determination of a reliable biomarker of successful activation of the vagus nerve using TENS. Currently, most studies focus on the assessment of heart rate variability (HRV) as a marker of the functioning of the autonomic nervous system.

Despite the physiological justification of HRV as a biomarker for TENS, the data on the effects of TENS on HRV are ambiguous. In some studies, a significant decrease in the ratio of spectral characteristics (LF/HF) in active TENS was found in comparison with fictitious stimulation (sham), which indicated an increase in the parasympathetic component of HRV. However, other studies have not revealed an increase in HRV.

Read the detailed description

Transcutaneous vagus nerve stimulation (TENS) involves the stimulation of the left and/or right auricular branch of the vagus nerve in the area of the cymba concha with low-frequency electrical impulses. The auricular branch of the vagus nerve runs superficially, which makes it a favorable target for non-invasive stimulation techniques to modulate vagal activity. It gained popularity due to minimal side effects and low cost.

This method is a new, cost-effective alternative to invasive cervical vagus nerve stimulation (iVNs), which is an FDA-approved treatment of depression resistant to the treatment, epilepsy and other pathologies.

The use of TENS has shown similar positive results as iVNs, for example, in reducing symptoms in patients with depression and changing the early visual processing of negative emotional stimuli in adolescent depression. Similarly, positive effects of TENS have also been found in chronic pain and epilepsy. These similarities in effects can be explained by the similarity of brain network activation achieved by iVNs and TENS.

The lack of similarity between behavioral studies and numerous theories of physiological processes in TENS make it necessary to determine a reliable biomarker of successful activation of the vagus nerve using TENS. Although many potential biomarkers have been proposed, most studies have focused on HRV.

Despite the physiological justification of HRV as a biomarker for TENS, the data on the effects of TENS on HRV are ambiguous. In some studies, a significant decrease in the ratio of spectral characteristics (LF/HF) in active TENS compared to fictitious stimulation (sham) was found, indicating an increase in the parasympathetic component of HRV.

However, other studies have not revealed an increase in HRV. Large methodological differences between studies, such as different stimulation devices, sides and places of stimulation, experimental schemes, reported HRV parameters and stimulation protocols, reduce comparability between studies.

One of the most striking examples is the use of various control conditions. While in most studies active TENS are compared with imitation of the earlobe as an independent variable, as recommended, in some studies active stimulation of the tragus was compared with a control state without stimulation or with a fictitious state without stimulation when the electrode is placed on the ear, but no electric current is applied.

The development of international agreed consensus guidelines on TENS research reporting should address these issues. Although TENS represents a potential treatment option for many disorders and it is an interesting tool for experimental research, it needs to be studied in an objective and reliable way before its true place as a neuro-immunomodulatory intervention can be determined.

The investigators plan to conduct a study on the assessment of TENS on the dynamics of HRV parameters with reporting according to the international consensus document https://www.frontiersin.org/articles/10.3389/fnhum.2020.568051/full#B235

02

Conditions studied

  • Vagus Nerve Stimulation
  • Heart Rate Variability

Keywords

  • auricular stimulation
  • auricular vagus nerve stimulation
  • heart rate
  • transcutaneous vagus nerve stimulation (TENS)
  • vagus nerve stimulation (VNS)
  • heart rate variability
  • power of high-frequency oscillations (HF)
  • power of low-frequency oscillations (LF)
  • power of very low frequency oscillations (VLF)
  • power of ultra-low frequency oscillations (ULF)
  • LF/HF
  • index centralization (IC)
  • index of vegetative balance (IVB)
03

In context

Lead sponsor

Bakulev Scientific Center of Cardiovascular Surgery is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sinus rhythm at the time of registration

Exclusion criteria

Exclusion Criteria:

  • Frequent ventricular / supraventricular extrasystole, 2d/3d degree AV Block
  • Taking glucocorticosteroids in the last 1 month
  • Taking any antiarrhythmics, except beta blockers
  • Severe chronic renal or liver pathology
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
140 participants (actual)

Study arms

  • Active comparator
    Active TENS

    Active will be performed with using a TENS device with an ear clip attached to the tragus of the left ear (which is innervated by auricular branch of the vagus nerve) at 20 Hz, 200 μs at a current just below discomfort threshold.

    Device: TENS

  • Sham comparator
    Sham TENS

    Sham will be performed with using a TENS device with an ear clip attached to the left earlobe (which is devoid of vegas innervation) at 20 Hz, 200 μs at a current just below discomfort threshold.

    Device: TENS

Interventions

  • DeviceTENS

    TENS stimulation will occur within 10 minutes. HRV parameters will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.

06

What researchers measure

Primary outcomes

  1. Dynamics of LF/HF

    Changes in the level of LF /HF relative to the initial and after the end of stimulation in the groups of active and fictitious stimulation

    Time frame: This parameter will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.

Secondary outcomes

  1. HR dynamics

    Changes in the HR level relative to the initial and after the end of stimulation in the groups of active and fictitious stimulation

    Time frame: This parameter will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.

  2. Dynamics of SDNN

    Changes in the level of SDNN relative to the initial and after the end of stimulation in the groups of active and fictitious stimulation

    Time frame: This parameter will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.

  3. Dynamics of IVB

    Changes in the level of IVB relative to the initial and after the end of stimulation in the groups of active and fictitious stimulation

    Time frame: This parameter will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.

  4. Dynamics of IC1

    Changes in the level of IC1 relative to the initial and after the end of stimulation in the groups of active and fictitious stimulation. IC1 (Index Centralization) = (HF+LF)/VLF

    Time frame: This parameter will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.

  5. Dynamics of IC2

    Changes in the level of IC2 relative to the initial and after the end of stimulation in the groups of active and fictitious stimulation. IC2 (Index Centralization) = (VHF+LF)/LF

    Time frame: This parameter will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.

  6. Dynamics of HF%

    Changes in the level of HF% relative to the initial and after the end of stimulation in the groups of active and fictitious stimulation

    Time frame: This parameter will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.

  7. Dynamics of LF%

    Changes in the level of LF% relative to the initial and after the end of stimulation in the groups of active and fictitious stimulation

    Time frame: This parameter will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.

  8. HF dynamics

    Changes in the HF level relative to the initial and after the end of stimulation in the groups of active and fictitious stimulation

    Time frame: This parameter will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.

  9. Dynamics of LF

    Changes in the level of LF relative to the initial and after the end of stimulation in the groups of active and fictitious stimulation

    Time frame: This parameter will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.

07

Study locations

3 sites
  • Federal Center for Cardiovascular Surgery (Astrakhan)
    Astrakhan, Russia
  • State Budget Public Health Institution Scientific Research Institute - Ochapovsky Regional Clinical Hospital
    Krasnodar, Russia
  • Bakulev National Medical Research Center for Cardiovascular Surgery
    Moscow, 121552, Russia
08

References and documents

Publications

  • Shvartz, V.; Sizhazhev, E.; Sokolskaya, M.; Koroleva, S.; Enginoev, S.; Kruchinova, S.; Shvartz, E.; Golukhova, E. The Effect of Short-Term Transcutaneous Electrical Stimulation of Auricular Vagus Nerve on Parameters of Heart Rate Variability. Data 2023, 8, 87. https://doi.org/10.3390/data8050087
  • Shvartz V.A., Sizhazhev E.M. Percutaneous stimulation of the auricular branch of the vagus: the potential of the method of treatment of different cardiovascular diseases. Clinical Physiology of Circulation. 2023; 20 (1): 5-15 (in Russ.). DOI: 10.24022/1814-6910-2023-20-1-5-15

Individual participant data

Plan to share: Yes — The datasets analyzed during the current study are publicly available. The data is available in the general repository "Open Science Framework" at the link

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: 2023

Access criteria: open access

Data sharing details ↗ · doi.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Mar 2026, 39 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2022
First posted
Jan 11, 2023
StartActual
Dec 1, 2022
Primary completionActual
Mar 1, 2026
CompletionActual
Apr 1, 2026
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05680337
Lead sponsor
Bakulev Scientific Center of Cardiovascular Surgery
Collaborators
State Budget Public Health Institution Scientific Research Institute - Ochapovsky Regional Clinical Hospital, Astrakhan Federal Centre For Cardiac Surgery
Responsible party
Vladimir A Shvartz, MD (MD, DM, Professor, Bakulev Scientific Center of Cardiovascular Surgery) — Principal investigator
First posted
Jan 11, 2023
Start date
Dec 1, 2022
Primary completion
Mar 1, 2026
Completion
Apr 1, 2026
Last update
Jul 20, 2026

Study contacts

Vladimir Shvartz
principal investigator · Bakoulev Scientific Center for Cardiovascular Surgery

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion